Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Provides free online access to Cloe Knowledge

1st Sep 2010 07:00

RNS Number : 9275R
Cyprotex PLC
01 September 2010
 



1 September 2010

 

 

Cyprotex PLC

("Cyprotex" or "the Company")

 

Cyprotex Announces Free Access to Physicochemical, ADME, and Pharmacokinetic Data of Marketed Drugs Through Its Visualisation Tool, Cloe® Knowledge

 

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that it is making available to researchers free online access to Cyprotex's database of the ADME and pharmacokinetic properties of marketed drugs via its online Cloe® Knowledge data visualisation and interpretation tool.

 

Free access is available via Cyprotex's Cloe® Gateway online portal: www.cloegateway.com.

 

Cloe® Knowledge categorisesmarketed drugs according to the 2009 WHO ATC/DDD drug index, allowing the database to be searchable by therapeutic area. Cloe® Knowledge's compound property visualisation tools allow relationships between different ADME and phys-chem properties to be viewed on either 2D or 3D scatter plots.

 

Commenting on the announcement, Dr Anthony D Baxter, Cyprotex's Chief Executive Officer, said:

 

"Cyprotex believes in sharing its knowledge with the scientific community. Our Cloe®Knowledge database of marketed drugs has been compiled and continuously updated based on extensive literature values and data generated in our own laboratories. Although some of the data are already available in the public domain, often they have not been conveniently compiled, and certainly not accessible through a powerful visualisation and interpretation tool such as the one Cloe® Knowledge provides. We believe that free access to these data via Cloe® Knowledge will help advance drug discovery, especially within the resource-constrained academic community."

 

Enquiries:

 

Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Mark Warburton, Chief Operating Officer and Legal Counsel

[email protected]

www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)

Tel: +44 (0) 203 205 7500

Shaun Dobson

[email protected]

Claes Spang

[email protected]

www.singerscm.com

Financial Dynamics

Tel: +44 (0) 20 7831 3113

Ben Brewerton

Ben Atwell

Mo Noonan

[email protected]

www.fd.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAFMGFRNMFGGZM

Related Shares:

CRX.L
FTSE 100 Latest
Value8,275.66
Change0.00